X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Novartis with Orchid Chemicals - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

NOVARTIS vs ORCHID PHARMA LTD - Comparison Results

NOVARTIS    Change

Novartis is a 76% subsidiary of Novartis AG - Switzerland and has a countrywide presence in the healthcare business. While pharmaceuticals contributes 70% to total revenues (FY10), generics (6%), consumer healthcare i.e. OTC (14%) and animal health (... More

ORCHID PHARMA LTD 
   Change

Orchid Chemicals & Pharmaceuticals Ltd. (Orchid) is today a globally recognized, integrated pharmaceutical company with core competencies in the development and manufacture of Active Pharmaceutical Ingredients (APIs) and Finished Dosage Forms as well... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    NOVARTIS ORCHID PHARMA LTD NOVARTIS/
ORCHID PHARMA LTD
 
P/E (TTM) x 393.4 -0.6 - View Chart
P/BV x 19.4 0.4 4,426.6% View Chart
Dividend Yield % 1.5 0.0 -  

Financials

 NOVARTIS   ORCHID PHARMA LTD
EQUITY SHARE DATA
    NOVARTIS
Mar-16
ORCHID PHARMA LTD
Sep-13
NOVARTIS/
ORCHID PHARMA LTD
5-Yr Chart
Click to enlarge
High Rs982194 506.2%   
Low Rs55635 1,589.1%   
Sales per share (Unadj.) Rs252.9276.5 91.5%  
Earnings per share (Unadj.) Rs62.1-79.2 -78.5%  
Cash flow per share (Unadj.) Rs63.3-43.5 -145.7%  
Dividends per share (Unadj.) Rs10.000-  
Dividend yield (eoy) %1.30-  
Book value per share (Unadj.) Rs363.653.9 674.2%  
Shares outstanding (eoy) m31.9670.45 45.4%   
Bonus/Rights/Conversions -ESOP-  
Price / Sales ratio x3.00.4 734.2%   
Avg P/E ratio x12.4-1.4 -856.2%  
P/CF ratio (eoy) x12.2-2.6 -461.1%  
Price / Book Value ratio x2.12.1 99.6%  
Dividend payout %16.10-   
Avg Mkt Cap Rs m24,5808,067 304.7%   
No. of employees `0000.82.8 26.9%   
Total wages/salary Rs m1,8012,527 71.3%   
Avg. sales/employee Rs Th10,748.96,956.1 154.5%   
Avg. wages/employee Rs Th2,395.2902.5 265.4%   
Avg. net profit/employee Rs Th2,641.1-1,993.0 -132.5%   
INCOME DATA
Net Sales Rs m8,08319,477 41.5%  
Other income Rs m829407 203.7%   
Total revenues Rs m8,91319,884 44.8%   
Gross profit Rs m2341,103 21.2%  
Depreciation Rs m372,519 1.5%   
Interest Rs m25,227 0.0%   
Profit before tax Rs m1,025-6,236 -16.4%   
Minority Interest Rs m020 0.0%   
Prior Period Items Rs m170-   
Extraordinary Inc (Exp) Rs m1,696511 332.0%   
Tax Rs m752-125 -600.6%   
Profit after tax Rs m1,986-5,580 -35.6%  
Gross profit margin %2.95.7 51.2%  
Effective tax rate %73.42.0 3,654.0%   
Net profit margin %24.6-28.7 -85.8%  
BALANCE SHEET DATA
Current assets Rs m12,67811,014 115.1%   
Current liabilities Rs m2,43332,060 7.6%   
Net working cap to sales %126.7-108.1 -117.3%  
Current ratio x5.20.3 1,516.8%  
Inventory Days Days3395 34.5%  
Debtors Days Days2234 67.0%  
Net fixed assets Rs m6929,440 0.2%   
Share capital Rs m160705 22.7%   
"Free" reserves Rs m11,4602,043 561.0%   
Net worth Rs m11,6213,800 305.8%   
Long term debt Rs m09,018 0.0%   
Total assets Rs m14,40046,510 31.0%  
Interest coverage x570.5-0.2 -295,412.1%   
Debt to equity ratio x02.4 0.0%  
Sales to assets ratio x0.60.4 134.0%   
Return on assets %13.8-0.8 -1,816.4%  
Return on equity %17.1-146.9 -11.6%  
Return on capital %23.6-3.7 -631.3%  
Exports to sales %0.737.9 2.0%   
Imports to sales %18.622.6 82.2%   
Exports (fob) Rs m607,378 0.8%   
Imports (cif) Rs m1,5034,406 34.1%   
Fx inflow Rs m1867,513 2.5%   
Fx outflow Rs m1,8215,649 32.2%   
Net fx Rs m-1,6351,865 -87.7%   
CASH FLOW
From Operations Rs m2,5311,682 150.5%  
From Investments Rs m-8,270-9,860 83.9%  
From Financial Activity Rs m-3866,644 -5.8%  
Net Cashflow Rs m-6,125-1,535 399.0%  

Share Holding

Indian Promoters % 0.0 32.3 -  
Foreign collaborators % 75.0 0.0 -  
Indian inst/Mut Fund % 2.0 4.6 43.5%  
FIIs % 1.6 3.3 48.5%  
ADR/GDR % 0.0 4.6 -  
Free float % 21.5 55.3 38.9%  
Shareholders   41,647 84,811 49.1%  
Pledged promoter(s) holding % 0.0 54.9 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare NOVARTIS With:   CIPLA  PFIZER  ALEMBIC PHARMA  SHASUN PHARMA  SANOFI INDIA  

Compare NOVARTIS With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex, Nifty Close at Record Highs; Bank & Realty Stocks Rally(Closing)

After opening the day marginally higher, Indian share markets extended gains in the afternoon session after the government decided to cut tax rates on certain products and services.

Related Views on News

Shalby Ltd. (IPO)

Dec 2, 2017

Should you subscribe to the IPO of Shalby Ltd?

Sun Pharma: Tough US Scenario Continues to Hit Business (Quarterly Results Update - Detailed)

Nov 20, 2017

The company's India business recovers but the pricing pressure and USFDA issues continue to mar the US revenues.

Dr Reddy's: No Respite from Pricing Pressure in the US (Quarterly Results Update - Detailed)

Nov 13, 2017

Pricing pressure continued to haunt Dr Reddy's although there was a significant improvement in its businesses sequentially.

Cipla: Strong Recovery Post GST (Quarterly Results Update - Detailed)

Nov 10, 2017

Cipla's India business recovers strongly this quarter post the GST issues in the first quarter of this fiscal.

Glenmark: Most Geographies Show Weak Growth (Quarterly Results Update - Detailed)

Nov 7, 2017

Poor show in the US, Latam and India hit profits during the quarter.

More Views on News

Most Popular

Retail Investors or Chickens Waiting to Get Slaughtered in the Stock Market?(Vivek Kaul's Diary)

Jan 9, 2018

The price to earnings ratio of the Nifty 50 is very close to all-time high levels.

Best ELSS Funds In 2018: Don't Blindly Chase Top Performers(Outside View)

Jan 10, 2018

As the tax-saving season begins, investors hunt for the best ELSS funds for 2018. PersonalFN provides a list of the top ELSS mutual funds of the past year.

Bitcoin Beginners Should Do These Three Things...(Smart Contrarian)

Jan 10, 2018

Three simple points to keep in mind before you consider buying bitcoin.

Resolutions for 2018 - by others(The Honest Truth)

Jan 8, 2018

Ten quirky new year resolutions. Guess by whom?

Did GST and Notebandi Help? Sherlock Holmes Finds Out...(The 5 Minute Wrapup)

Jan 13, 2018

Discussions with my cousin helped me understand the situation on Ground Zero - after the demonetization and GST upheaval. Here's what that means for listed companies...

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

NOVARTIS SHARE PRICE


Jan 19, 2018 (Close)

TRACK NOVARTIS

  • Track your investment in NOVARTIS with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

NOVARTIS 8-QTR ANALYSIS

COMPARE NOVARTIS WITH

MARKET STATS